Cargando…

Insulin-Degrading Enzyme Is a Non Proteasomal Target of Carfilzomib and Affects the 20S Proteasome Inhibition by the Drug

Carfilzomib is a last generation proteasome inhibitor (PI) with proven clinical efficacy in the treatment of relapsed/refractory multiple myeloma. This drug is considered to be extremely specific in inhibiting the chymotrypsin-like activity of the 20S proteasome, encoded by the β5 subunit, overcomin...

Descripción completa

Detalles Bibliográficos
Autores principales:	Tundo, Grazia Raffaella, Sbardella, Diego, Oddone, Francesco, Grasso, Giuseppe, Marini, Stefano, Atzori, Maria Grazia, Santoro, Anna Maria, Milardi, Danilo, Bellia, Francesco, Macari, Gabriele, Graziani, Grazia, Polticelli, Fabio, Cascio, Paolo, Parravano, Mariacristina, Coletta, Massimo
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2022
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8869475/ https://www.ncbi.nlm.nih.gov/pubmed/35204815 http://dx.doi.org/10.3390/biom12020315

Ejemplares similares

A novel and atypical NF-KB pro-inflammatory program regulated by a CamKII-proteasome axis is involved in the early activation of Muller glia by high glucose
por: Sbardella, Diego, et al.
Publicado: (2022)

The proteasome as a druggable target with multiple therapeutic potentialities: Cutting and non-cutting edges
por: Tundo, G.R., et al.
Publicado: (2020)

The Insulin-Degrading Enzyme from Structure to Allosteric Modulation: New Perspectives for Drug Design
por: Tundo, Grazia Raffaella, et al.
Publicado: (2023)

Cationic porphyrins are tunable gatekeepers of the 20S proteasome
por: Santoro, Anna M., et al.
Publicado: (2016)

Proteasome Activity Is Affected by Fluctuations in Insulin-Degrading Enzyme Distribution
por: Sbardella, Diego, et al.
Publicado: (2015)

Modulation of the 20S Proteasome Activity by Porphyrin Derivatives Is Steered through Their Charge Distribution
por: Persico, Marco, et al.
Publicado: (2022)

Dexamethasone Downregulates Autophagy through Accelerated Turn-Over of the Ulk-1 Complex in a Trabecular Meshwork Cells Strain: Insights on Steroid-Induced Glaucoma Pathogenesis
por: Sbardella, Diego, et al.
Publicado: (2021)

Electrostatic Map Of Proteasome α-Rings Encodes The Design of Allosteric Porphyrin-Based Inhibitors Able To Affect 20S Conformation By Cooperative Binding
por: Dato, Antonio Di, et al.
Publicado: (2017)

Cooperative Binding of the Cationic Porphyrin Tris-T4 Enhances Catalytic Activity of 20S Proteasome Unveiling a Complex Distribution of Functional States
por: Santoro, Anna Maria, et al.
Publicado: (2020)

At the Cutting Edge against Cancer: A Perspective on Immunoproteasome and Immune Checkpoints Modulation as a Potential Therapeutic Intervention
por: Tundo, Grazia R., et al.
Publicado: (2021)

Proteasome inhibition by bortezomib parallels a reduction in head and neck cancer cells growth, and an increase in tumor-infiltrating immune cells
por: Benvenuto, Monica, et al.
Publicado: (2021)

Investigating the Vascular Toxicity Outcomes of the Irreversible Proteasome Inhibitor Carfilzomib
por: Efentakis, Panagiotis, et al.
Publicado: (2020)

Spasmogenic Effects of the Proteasome Inhibitor Carfilzomib on Coronary Resistance, Vascular Tone and Reactivity
por: Chen-Scarabelli, Carol, et al.
Publicado: (2017)

Somatostatin Modulates Insulin-Degrading-Enzyme Metabolism: Implications for the Regulation of Microglia Activity in AD
por: Tundo, Grazia, et al.
Publicado: (2012)

H727 cells are inherently resistant to the proteasome inhibitor carfilzomib, yet require proteasome activity for cell survival and growth
por: Lee, Min Jae, et al.
Publicado: (2019)

Carfilzomib: A Promising Proteasome Inhibitor for the Treatment of Relapsed and Refractory Multiple Myeloma
por: Jayaweera, Shansa Pranami E., et al.
Publicado: (2021)

Regulating Proteasome Activity
por: Cascio, Paolo, et al.
Publicado: (2022)

Citicoline in Ophthalmological Neurodegenerative Disease: A Comprehensive Review
por: Oddone, Francesco, et al.
Publicado: (2021)

Nelfinavir augments proteasome inhibition by bortezomib in myeloma cells and overcomes bortezomib and carfilzomib resistance
por: Kraus, M, et al.
Publicado: (2013)

Second-generation proteasome inhibitor carfilzomib sensitizes neuroblastoma cells to doxorubicin-induced apoptosis
por: Guan, Shan, et al.
Publicado: (2016)

Clinical activity of carfilzomib correlates with inhibition of multiple proteasome subunits: application of a novel pharmacodynamic assay
por: Lee, Susan J., et al.
Publicado: (2016)

Copper(II) ions affect the gating dynamics of the 20S proteasome: a molecular and in cell study
por: Santoro, Anna Maria, et al.
Publicado: (2016)

Polymer micelle formulation for the proteasome inhibitor drug carfilzomib: Anticancer efficacy and pharmacokinetic studies in mice
por: Park, Ji Eun, et al.
Publicado: (2017)

Electronic Circular Dichroism Detects Conformational Changes Associated with Proteasome Gating Confirmed Using AFM Imaging
por: D’Urso, Alessandro, et al.
Publicado: (2023)

The novel proteasome inhibitor carfilzomib activates and enhances extrinsic apoptosis involving stabilization of death receptor 5
por: Han, Bo, et al.
Publicado: (2015)

Second-generation proteasome inhibitor carfilzomib enhances doxorubicin-induced cytotoxicity and apoptosis in breast cancer cells
por: Shi, Yonghua, et al.
Publicado: (2016)

Proteasome Inhibition by Carfilzomib Induced Apotosis and Autophagy in a T-cell Acute Lymphoblastic Leukemia Cell Line
por: Hosseini, Maryam Sadat, et al.
Publicado: (2019)

PA28αβ: The Enigmatic Magic Ring of the Proteasome?
por: Cascio, Paolo
Publicado: (2014)

PA28γ: New Insights on an Ancient Proteasome Activator
por: Cascio, Paolo
Publicado: (2021)

Modelling Proteasome and Proteasome Regulator Activities
por: Liepe, Juliane, et al.
Publicado: (2014)

Deubiquitination Reactions on the Proteasome for Proteasome Versatility
por: Shin, Ji Yeong, et al.
Publicado: (2020)

Mucin 20 modulates proteasome capacity through c‐Met signalling to increase carfilzomib sensitivity in mantle cell lymphoma
por: Wang, Xiaobin, et al.
Publicado: (2021)

Targeting Tumor-Associated Macrophages to Increase the Efficacy of Immune Checkpoint Inhibitors: A Glimpse into Novel Therapeutic Approaches for Metastatic Melanoma
por: Ceci, Claudia, et al.
Publicado: (2020)

Role of VEGFs/VEGFR-1 Signaling and Its Inhibition in Modulating Tumor Invasion: Experimental Evidence in Different Metastatic Cancer Models
por: Ceci, Claudia, et al.
Publicado: (2020)

Proteasome in action: substrate degradation by the 26S proteasome
por: Sahu, Indrajit, et al.
Publicado: (2021)

Synergistic effects of proteasome inhibitor carfilzomib in combination with tyrosine kinase inhibitors in imatinib-sensitive and -resistant chronic myeloid leukemia models
por: Crawford, L J, et al.
Publicado: (2014)

Proteasome inhibitors bortezomib and carfilzomib used for the treatment of multiple myeloma do not inhibit the serine protease HtrA2/Omi
por: Csizmadia, Vilmos, et al.
Publicado: (2016)

Mechanistic Pharmacokinetic/Pharmacodynamic Modeling in Support of a Patient-Convenient, Longer Dosing Interval for Carfilzomib, a Covalent Inhibitor of the Proteasome
por: Yago, Marc R., et al.
Publicado: (2023)

Functional and Spectroscopic Characterization of Chlamydomonas reinhardtii Truncated Hemoglobins
por: Ciaccio, Chiara, et al.
Publicado: (2015)

Rethinking Proteasome Evolution: Two Novel Bacterial Proteasomes
por: Valas, Ruben E., et al.
Publicado: (2008)

Cannot write session to /tmp/vufind_sessions/sess_8ubl1pnbv33tdg727ldifd6ba7